• SPX
  • $5,893.62
  • 0.39 %
  • $23.00
  • DJI
  • $43,389.60
  • -0.13 %
  • -$55.39
  • N225
  • $38,429.37
  • 0.55 %
  • $208.52
  • FTSE
  • $8,109.32
  • 0.57 %
  • $45.71
  • IXIC
  • $18,791.81
  • 0.6 %
  • $111.69
Oculis Holding AG (OCS) Stock Price, News & Analysis

Oculis Holding AG (OCS) Stock Price, News & Analysis

Currency in USD Disclaimer

$14.67

$0.53

(3.72%)

Day's range
$14.18
Day's range
$14.88
50-day range
$11.78
Day's range
$18
  • Country: CH
  • ISIN: CH1242303498
52 wk range
$9.6
Day's range
$18
  • CEO: Dr. Riad Sherif M.B.A., M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.75
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (OCS)
  • Company Oculis Holding AG
  • Price $14.67
  • Changes Percentage (3.72%)
  • Change $0.53
  • Day Low $14.18
  • Day High $14.88
  • Year High $18.00

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/17/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $33.50
  • High Stock Price Target $37.00
  • Low Stock Price Target $30.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $0.18
  • Trailing P/E Ratio 65.83
  • Forward P/E Ratio 65.83
  • P/E Growth 65.83
  • Net Income $-88,802,000

Income Statement

Quarterly

Annual

Latest News of OCS

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Oculis Holding AG Frequently Asked Questions

  • What is the Oculis Holding AG stock price today?

    Today's price of Oculis Holding AG is $14.67 — it has increased by +3.72% in the past 24 hours. Watch Oculis Holding AG stock price performance more closely on the chart.

  • Does Oculis Holding AG release reports?

    Yes, you can track Oculis Holding AG's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Oculis Holding AG stock forecast?

    Watch the Oculis Holding AG chart and read a more detailed Oculis Holding AG stock forecast to see what analysts suggest you do with its shares.

  • What is Oculis Holding AG stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Oculis Holding AG stock ticker.

  • How to buy Oculis Holding AG stocks?

    Like other stocks, OCS shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Oculis Holding AG's EBITDA?

    Oculis Holding AG measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Oculis Holding AG’s financial statements.

  • What is the Oculis Holding AG's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -100.5685164213, which equates to approximately -10,056.85%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Oculis Holding AG stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Oculis Holding AG's financials relevant news, and technical analysis. Oculis Holding AG's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Oculis Holding AG stock currently indicates a “sell” signal. For more insights, review Oculis Holding AG’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.